Article citationsMore>>

D. C. Musch, B. W. Gillespie, P. R. Lichter, et al., “Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study: The Impact of Treatment and Other Baseline Factors,” Ophthalmology, Vol. 116, No. 2, 2009, pp. 200-207.
http://dx.doi.org/10.1016/j.ophtha.2008.08.051

has been cited by the following article:

• TITLE: Nanobiotechnology in the Management of Glaucoma

  AUTHORS: Pho Nguyen, Alex Huang, Samuel C. Yiu

  KEYWORDS: Glaucoma; Nanotechnology; Nanomedicine; Drug Delivery; Wound Healing; Nanoparticle

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.3 No.4, November 11, 2013

  ABSTRACT: As the prevalence of glaucoma continues to rise, clinicians and researchers are confronted with an age-old problem: how to reduce risk factors and preserve vision in glaucoma. Current management options revolve around a validated paradigm—intraocular pressure reduction. Active investigations to improve drug delivery efficacy and surgical outcomes are flourishing. This article aims to provide the interested readers with a review of recent discoveries in nanobiotechnology for the management of glaucoma. Targeted drug-delivery systems using mesoscale vectors demonstrate promising delivery profiles. The utility of nanoparticulate therapies to support retinal ganglion cell survival is being investigated. Studies to modulate tissue regeneration and remodeling and improve post-trabeculectomy outcomes are underway. Though these modalities promise new avenues to manage glaucoma, immediate market availability is not anticipated soon.